{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:52:19Z","timestamp":1793436739114,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Assist Reprod Genet"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>To determine the impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcome. The main purpose and research question of the study is to determine the impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Prospective study: 67 breast cancer patients between 18 and 40\u00a0years old, undergoing a fertility preservation by means of oocyte storage were considered. Inclusions criteria for the study were age between 18 and 40\u00a0years old, BMI between 18 and 28, breast cancer neoplasm stage I and II according to American Joint Committee on Cancer classification (2017) and no metastasis. Exclusion criteria: age over 40\u00a0years old, BMI\u2009&lt;\u200918 and &gt;\u200928, breast cancer neoplasm stage III and IV and do not performed the BRCA test. A total of 21 patients had not performed the test and were excluded. Patients were divided into four groups: Group A was composed by 11 breast cancer patients with BRCA 1 mutations, Group B was composed by 11 breast cancer patients with BRCA 2 mutations, Group C was composed by 24 women with breast cancer without BRCA mutations, and Group D (control) was composed by 181 normal women.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Group A showed significant lower AMH levels compared to Group C and D (1.2\u2009\u00b1\u20091.1 vs 4.5\u2009\u00b1\u20094.1 <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 and 1.2\u2009\u00b1\u20091.1 vs 3.8\u2009\u00b1\u20092.5 <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). BRCA1 mutated patients showed a significant lower rate of mature oocytes (MII) compared to Group C (3.1\u2009\u00b1\u20092.3 vs 7.2\u2009\u00b1\u20094.4 <jats:italic>p<\/jats:italic>\u2009&lt;\u20090,05) and Group D (3.1\u2009\u00b1\u20092.3 vs 7.3\u2009\u00b1\u20093.4; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090,05). Breast cancer patients needed a higher dose of gonadotropins compared to controls (Group A 2206\u2009\u00b1\u20091392 Group B2047.5\u2009\u00b1\u2009829.9 Group C 2106\u2009\u00b1\u20091336 Group D 1597\u2009\u00b1\u2009709 <jats:italic>p<\/jats:italic>\u2009&lt;\u20090,05). No significant differences were found among the groups considering basal FSH levels, duration of stimulation, number of developed follicles, and number of total retrieved oocytes. Regarding BRCA2 mutation, no effect on fertility was shown in this study.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The study showed that BRCA1 patients had a higher risk of premature ovarian insufficiency (POI) confirmed by a diminished ovarian reserve and a lower number of mature oocytes suitable for cryopreservation.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s10815-019-01658-9","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T08:11:52Z","timestamp":1586247112000},"page":"709-715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5892-480X","authenticated-orcid":false,"given":"Eleonora","family":"Porcu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Maria","family":"Cillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Sacilotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Notarangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Damiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dirodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Roncarati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,24]]},"reference":[{"key":"1658_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/jayao.2016.0009","volume":"5","author":"S Giordano","year":"2016","unstructured":"Giordano S, Garrett-Mayer E, Mittal N, Smith K, Shulman L, Passaglia C, et al. Association of BRCA1 mutations with impaired ovarian reserve: connection between infertility and breast\/ovarian Cancer risk. J Adolesc Young Adul. 2016;5:337\u201343.","journal-title":"J Adolesc Young Adul"},{"key":"1658_CR2","doi-asserted-by":"publisher","first-page":"172ra21","DOI":"10.1126\/scitranslmed.3004925","volume":"5","author":"S Titus","year":"2013","unstructured":"Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5:172ra21.","journal-title":"Sci Transl Med"},{"issue":"6","key":"1658_CR3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.fertnstert.2014.08.014","volume":"102","author":"ET Wang","year":"2014","unstructured":"Wang ET, Pisarska MD, Bresee C, Chen YD, Lester J, Afshar Y, et al. BRCA1 germline mutations may be associated with reduced ovarian reserve. Fertil Steril. 2014;102(6):1723\u20138.","journal-title":"Fertil Steril"},{"key":"1658_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fendo.2019.00235","volume":"10","author":"KA Son","year":"2019","unstructured":"Son KA, Lee DY, Choi D. Association of BRCA mutations and anti-mullerian hormone level in young breast Cancer patients. Front Endocrinol (Lausanne). 2019;10:235.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1658_CR5","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1200\/JCO.2009.24.2057","volume":"28","author":"K Oktay","year":"2010","unstructured":"Oktay K. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast\/ovarian cancer risks (vol 28, pg 240, 2010). J Clin Oncol. 2010;28:4664.","journal-title":"J Clin Oncol"},{"key":"1658_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1095\/biolreprod.115.132290","volume":"93","author":"K Oktay","year":"2015","unstructured":"Oktay K, Turan V, Titus S, Stobezki R, Liu L. BRCA mutations, DNA repair deficiency, and ovarian aging. Biol Reprod. 2015;93:67.","journal-title":"Biol Reprod"},{"key":"1658_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1210\/er.2016-1047","volume":"37","author":"EJ Tucker","year":"2016","unstructured":"Tucker EJ, Grover SR, Bachelot A, Touraine P, Sinclair AH. Premature ovarian insufficiency: new perspectives on genetic cause and phenotypic Spectrum. Endocr Rev. 2016;37:609\u201335.","journal-title":"Endocr Rev"},{"key":"1658_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1365-2265.2007.03073.x","volume":"68","author":"CK Welt","year":"2008","unstructured":"Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol. 2008;68:499\u2013509.","journal-title":"Clin Endocrinol"},{"key":"1658_CR9","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s10815-015-0595-y","volume":"32","author":"J Cohen","year":"2015","unstructured":"Cohen J, Chabbert-Buffet N, Darai E. Diminished ovarian reserve, premature ovarian failure, poor ovarian responder--a plea for universal definitions. J Assist Reprod Genet. 2015;32:1709\u201312.","journal-title":"J Assist Reprod Genet"},{"key":"1658_CR10","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1200\/JCO.2013.49.3007","volume":"31","author":"IM Collins","year":"2013","unstructured":"Collins IM, Milne RL, McLachlan SA, Friedlander M, Hickey M, Weideman PC, et al. Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results From the Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer. J Clin Oncol. 2013;31:3920.","journal-title":"J Clin Oncol"},{"key":"1658_CR11","first-page":"1652","volume":"119","author":"WT Lin","year":"2013","unstructured":"Lin WT, Beattie M, Chen LM, Oktay K, Crawford SL, Gold EB, et al. Comparison of age at natural menopause in BRCA1\/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer-Am Cancer Soc. 2013;119:1652\u20139.","journal-title":"Cancer-Am Cancer Soc"},{"key":"1658_CR12","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2012.47.7893","volume":"31","author":"A Valentini","year":"2013","unstructured":"Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C, et al. Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2013;31:3914.","journal-title":"J Clin Oncol"},{"key":"1658_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.fertnstert.2011.10.014","volume":"97","author":"S Friedler","year":"2012","unstructured":"Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril. 2012;97:125\u201333.","journal-title":"Fertil Steril"},{"key":"1658_CR14","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1200\/JCO.2013.49.2678","volume":"31","author":"AW Loren","year":"2013","unstructured":"Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500\u201310.","journal-title":"J Clin Oncol"},{"key":"1658_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1472-6483(10)61779-8","volume":"9","author":"A Agarwal","year":"2004","unstructured":"Agarwal A, Said TM. Implications of systemic malignancies on human fertility. Reprod BioMed Online. 2004;9:673\u20139.","journal-title":"Reprod BioMed Online"},{"key":"1658_CR16","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s10815-017-1014-3","volume":"34","author":"IAP Derks-Smeets","year":"2017","unstructured":"Derks-Smeets IAP, van Tilborg TC, van Montfoort A, Smits L, Torrance HL, Meijer-Hoogeveen M, et al. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF\/PGD. J Assist Reprod Genet. 2017;34:1475\u201382.","journal-title":"J Assist Reprod Genet"},{"key":"1658_CR17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10815-016-0689-1","volume":"33","author":"J Lekovich","year":"2016","unstructured":"Lekovich J, Lobel ALS, Stewart JD, Pereira N, Kligman I, Rosenwaks Z. Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies. J Assist Reprod Genet. 2016;33:657\u201362.","journal-title":"J Assist Reprod Genet"},{"key":"1658_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/annonc\/mdx639","volume":"29","author":"M Lambertini","year":"2018","unstructured":"Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA Jr, Desir J, et al. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol. 2018;29:237\u201343.","journal-title":"Ann Oncol"},{"key":"1658_CR19","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.fertnstert.2015.07.1162","volume":"104","author":"M Shapira","year":"2015","unstructured":"Shapira M, Raanani H, Feldman B, Srebnik N, Dereck-Haim S, Manela D, et al. BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles. Fertil Steril. 2015;104:1162\u20137.","journal-title":"Fertil Steril"},{"key":"1658_CR20","doi-asserted-by":"crossref","unstructured":"Turan V, Bedoschi G, Emirdar V, Moy F, Oktay K. Ovarian stimulation in patients with Cancer: impact of Letrozole and BRCA mutations on fertility preservation cycle outcomes. Reprod Sci. 2017:1933719117728800.","DOI":"10.1177\/1933719117728800"},{"key":"1658_CR21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.fertnstert.2018.10.014","volume":"111","author":"V Gunnala","year":"2019","unstructured":"Gunnala V, Fields J, Irani M, D'Angelo D, Xu K, Schattman G, et al. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation. Fertil Steril. 2019;111:363\u201371.","journal-title":"Fertil Steril"},{"issue":"5","key":"1658_CR22","first-page":"172ra21","volume":"172","author":"S Titus","year":"2013","unstructured":"Titus S, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;172(5):172ra21.","journal-title":"Sci Transl Med"},{"key":"1658_CR23","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3109\/09513590.2013.819083","volume":"29","author":"A Revelli","year":"2013","unstructured":"Revelli A, Porcu E, Levi Setti PE, Delle Piane L, Merlo DF, Anserini P. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol. 2013;29:993\u20136.","journal-title":"Gynecol Endocrinol"},{"issue":"107","key":"1658_CR24","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.fertnstert.2017.03.018","volume":"5","author":"L Johnson","year":"2017","unstructured":"Johnson L, et al. Antimullerian hormone levels are lower in BRCA2 mutation carriers. Fertil Steril. 2017;5(107):1256.","journal-title":"Fertil Steril"},{"issue":"5","key":"1658_CR25","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/humrep\/dew044","volume":"31","author":"KA Phillips","year":"2016","unstructured":"Phillips KA, Collins IM, Milne RL, McLachlan S, Friedlander M, Hickey M, et al. Anti-Mullerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Hum Reprod. 2016;31(5):1126\u201332.","journal-title":"Hum Reprod"},{"issue":"2","key":"1658_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/IGC.0000000000000058","volume":"24","author":"R Michaelson-Cohen","year":"2014","unstructured":"Michaelson-Cohen R, Mor P, Srebnik N, Beller U, Levy-Lahad E, Eldar-Geva T. BRCA mutation carriers do not have compromised ovarian reserve. Int J Gynecol Cancer. 2014;24(2):233\u20137.","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"1658_CR27","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1093\/humrep\/dew242","volume":"31","author":"TC van Tilborg","year":"2016","unstructured":"van Tilborg TC, et al. Serum AMH levels in healthy women from BRCA1\/2 mutated families: are they reduced? Hum Reprod. 2016;31(11):2651\u20139.","journal-title":"Hum Reprod"},{"issue":"4","key":"1658_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/jayao.2016.0009","volume":"5","author":"S Giordano","year":"2016","unstructured":"Giordano S, Garrett-Mayer E, Mittal N, Smith K, Shulman L, Passaglia C, et al. Association of BRCA1 mutations with impaired ovarian reserve: connection between infertility and breast\/ovarian cancer risk. J Adolesc Young Adult Oncol. 2016;5(4):337\u201343.","journal-title":"J Adolesc Young Adult Oncol"},{"key":"1658_CR29","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1210\/jc.2017-00765","volume":"102","author":"W Lin","year":"2017","unstructured":"Lin W, Titus S, Moy F, Ginsburg ES, Oktay K. Ovarian aging in women with BRCA germline mutations. J Clin Endocrinol Metab. 2017;102:3839\u201347.","journal-title":"J Clin Endocrinol Metab"},{"key":"1658_CR30","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1158\/0008-5472.CAN-13-2611","volume":"74","author":"KI Savage","year":"2014","unstructured":"Savage KI, Matchett KB, Barros EM, Cooper KM, Irwin GW, Gorski JJ, et al. BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability. Cancer Res. 2014;74:2773\u201384.","journal-title":"Cancer Res"},{"key":"1658_CR31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1158\/1055-9965.EPI-09-0807","volume":"19","author":"ME Reichman","year":"2010","unstructured":"Reichman ME, Altekruse S, Li CI, Chen VW, Deapen D, Potts M, et al. Feasibility study for collection of HER2 data by National Cancer Institute (NCI) surveillance, epidemiology, and end results (SEER) program central cancer registries. Cancer Epidemiol Biomark Prev. 2010;19:144\u20137.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1658_CR32","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1200\/JCO.1999.17.8.2365","volume":"17","author":"PJ Goodwin","year":"1999","unstructured":"Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365\u201370.","journal-title":"J Clin Oncol"},{"key":"1658_CR33","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1472-6483(10)60204-0","volume":"17","author":"E Porcu","year":"2008","unstructured":"Porcu E, Venturoli S, Damiano G, Ciotti PM, Notarangelo L, Paradisi R, et al. Healthy twins delivered after oocyte cryopreservation and bilateral ovariectomy for ovarian cancer. Reprod BioMed Online. 2008;17:265\u20137.","journal-title":"Reprod BioMed Online"},{"issue":"Suppl 1","key":"1658_CR34","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.ejogrb.2003.11.004","volume":"113","author":"E Porcu","year":"2004","unstructured":"Porcu E, Fabbri R, Damiano G, Fratto R, Giunchi S, Venturoli S. Oocyte cryopreservation in oncological patients. Eur J Obstet Gynecol Reprod Biol. 2004;113(Suppl 1):S14\u20136.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"6","key":"1658_CR35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/MED.0b013e3283199129","volume":"15","author":"E Porcu","year":"2008","unstructured":"Porcu E, Bazzocchi A, Notarangelo L, Paradisi R, Landolfo C, Venturoli S. Human oocyte cryopreservation in infertility and oncology. Curr Opin Endocrinol Diabetes. 2008;15(6):529\u201335.","journal-title":"Curr Opin Endocrinol Diabetes"},{"key":"1658_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/humrep\/dex356","volume":"33","author":"FA Peccatori","year":"2018","unstructured":"Peccatori FA, Mangili G, Bergamini A, Filippi F, Martinelli F, Ferrari F, et al. Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? Hum Reprod. 2018;33:181\u20137.","journal-title":"Hum Reprod"}],"container-title":["Journal of Assisted Reproduction and Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-019-01658-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10815-019-01658-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-019-01658-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:34:59Z","timestamp":1608683699000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10815-019-01658-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,24]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1658"],"URL":"https:\/\/doi.org\/10.1007\/s10815-019-01658-9","relation":{},"ISSN":["1058-0468","1573-7330"],"issn-type":[{"value":"1058-0468","type":"print"},{"value":"1573-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,24]]},"assertion":[{"value":"7 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}